Loading clinical trials...
Loading clinical trials...
A Phase I Study of Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease (SR-aGVHD) or Treatment-refractory Acute Graft-versus-host Disease (TR-aGVHD)
Conditions
Interventions
Neihulizumab (ALTB-168)
Locations
13
United States
City of Hope
Duarte, California, United States
David Geffen School of Medicine at UCLA
Los Angeles, California, United States
University of Miami - Sylvester Comprehensive Cancer Center
Miami, Florida, United States
Emory University
Atlanta, Georgia, United States
University of Chicago
Chicago, Illinois, United States
The University of Kansas Cancer Center
Westwood, Kansas, United States
Start Date
May 31, 2018
Primary Completion Date
September 30, 2022
Completion Date
December 31, 2022
Last Updated
January 19, 2023
Lead Sponsor
AltruBio Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions